Conditions: Resistant Hypertension
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 60
Healthy volunteers: no

Brief summary:
The study was to determine the safe and effective dose of TBC3711 in patients with uncontrolled high blood pressure while already taking blood pressure medications.

Detailed description:
The study was stopped due to Pfizer (sponsor) decision that the compound would not be involved in any further clinical development for the indication of resistant hypertension on 05 August 2008. This decision was not based on any safety or efficacy concern.

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None

Interventions: intervention 1: Placebo intervention 2: TBC3711 intervention 3: TBC3711 intervention 4: TBC3711 intervention 5: TBC3711
Intervention descriptions: intervention 1: placebo tablet once daily for 12 weeks intervention 2: 10 mg tablets once daily for 10 weeks intervention 3: 50 mg tablet once daily for 10 weeks intervention 4: 100 mg tablet once daily for 10 weeks intervention 5: 200 mg tablet once daily for 10 weeks

Protocol document: